Literature DB >> 10931530

Proteasome inhibition results in increased poly-ADP-ribosylation: implications for neuron death.

J N Keller1, W R Markesbery.   

Abstract

This study demonstrates the ability of proteasome inhibitors (lactacystin, MG 115, MG 132) adenosine diphosphate to induce a time- and dose-dependent increase in poly-ADP-ribosylation (PAR) in the neural PC6 cell line, a subclone of PC12 cells. Elevated levels of PAR contribute to the toxicity associated with impaired proteasome activity, based on the ability of PAR inhibitors to ameliorate the toxicity associated with the application of lactacystin, MG 115, and MG 132. Proteasome inhibitors induced the accumulation of PAR and neuron death in primary hippocampal neuron cultures, which were both ameliorated by treatment with PAR inhibitors. Together, these data indicate a role for increased PAR in the toxicity associated with proteasome inhibition, and suggest that inhibitors of PAR may provide neuroprotection in conditions where proteasome inhibition occurs. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931530     DOI: 10.1002/1097-4547(20000815)61:4<436::AID-JNR10>3.0.CO;2-Z

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  11 in total

1.  Essential role of ubiquitin C-terminal hydrolases UCHL1 and UCHL3 in mammalian oocyte maturation.

Authors:  Namdori R Mtango; Miriam Sutovsky; Catherine A Vandevoort; Keith E Latham; Peter Sutovsky
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

2.  Circulating extracellular proteasome in the cerebrospinal fluid: a study on concentration and proteolytic activity.

Authors:  Oliver Mueller; Timur Anlasik; Jonas Wiedemann; Jan Thomassen; Jeremias Wohlschlaeger; Vincent Hagel; Kathy Keyvani; Isabel Schwieger; Burkhardt Dahlmann; Ulrich Sure; Stephan Urs Sixt
Journal:  J Mol Neurosci       Date:  2011-09-01       Impact factor: 3.444

Review 3.  The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

Authors:  Mario Di Napoli; BethAnn McLaughlin
Journal:  Curr Opin Investig Drugs       Date:  2005-07

4.  Neuron specific toxicity of oligomeric amyloid-β: role for JUN-kinase and oxidative stress.

Authors:  Philip J Ebenezer; Adam M Weidner; Harry LeVine; William R Markesbery; M Paul Murphy; Le Zhang; Kalavathi Dasuri; Sun Ok Fernandez-Kim; Annadora J Bruce-Keller; Elena Gavilán; Jeffrey N Keller
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  PTEN attenuates PIP3/Akt signaling in the cochlea of the aging CBA/J mouse.

Authors:  Su-Hua Sha; Fu-Quan Chen; Jochen Schacht
Journal:  Hear Res       Date:  2009-09-15       Impact factor: 3.208

Review 6.  Linkage between the proteasome pathway and neurodegenerative diseases and aging.

Authors:  Sophie Vigouroux; Marièle Briand; Yves Briand
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

7.  Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation.

Authors:  Benjamin B Gelman; Kimberly Schuenke
Journal:  J Neurovirol       Date:  2004-04       Impact factor: 2.643

Review 8.  Neuronal death in Alzheimer's disease and therapeutic opportunities.

Authors:  Rossen Donev; Martin Kolev; Bruno Millet; Johannes Thome
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

9.  Over-Activated Proteasome Mediates Neuroinflammation on Acute Intracerebral Hemorrhage in Rats.

Authors:  Hock-Kean Liew; Wei-Fen Hu; Peter Bor-Chian Lin; Po-Kai Wang; Andy Po-Yi Tsai; Cheng-Yoong Pang; Tsung-Ying Chen
Journal:  Cells       Date:  2019-10-27       Impact factor: 6.600

10.  UCHL1 and Proteasome in Blood Serum in Relation to Dietary Habits, Concentration of Selected Antioxidant Minerals and Total Antioxidant Status among Patients with Alzheimer's Disease.

Authors:  Sylwia Bogdan; Anna Puścion-Jakubik; Katarzyna Klimiuk; Katarzyna Socha; Jan Kochanowicz; Ewa Gorodkiewicz
Journal:  J Clin Med       Date:  2022-01-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.